Claims for Patent: 10,011,637

Summary for Patent: 10,011,637

Title:	Ultra-pure agonists of guanylate cyclase C, method of making and using same
Abstract:	The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Inventor(s):	Shailubhai; Kunwar (Audubon, PA), Comiskey; Stephen (Doylestown, PA), Feng; Rong (Langhorne, PA), Bai; Juncai (North Augusta, SC), Zhang; Ruoping (North Augusta, PA), Jia; Jun (Shanghai, CN), Zhou; Junfeng (Shanghai, CN), Zhao; Qiao (Shanghai, CN), Zhang; Guoqing (Shanghai, CN)
Assignee:	SYNERGY PHARMACEUTICALS, INC. (New York, NY)
Application Number:	14/896,019
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,011,637
Patent Claims:	1. A purified peptide comprising the GCC agonist amino acid sequence of SEQ ID NO: 1, wherein the purified peptide has the following characteristics: a) has a bulk density of not greater than 0.1 g/mL; b) contains less than 50 ppm acetamide; c) less than 0.25% alpha-Asp-9-plecanatide (RRT 1.33) per total weight of peptide; and d) less than 0.05% trifluoroacetic acid (TFA) per total weight of peptide. 2. The purified peptide of claim 1, wherein the peptide is stable at 25.degree. C. for at least three months. 3. The purified peptide of claim 1, wherein the peptide has a particle size distribution characterized by: a) a D10 value of between about 2-15 .mu.m; b) a D50 value of between about 15-50 .mu.m; and c) a D90 value of between about 40-80 .mu.m when measured by light scattering with liquid dispersant. 4. The purified peptide of claim 1, wherein the peptide has a bulk density of not greater than 0.06 g/mL. 5. The purified peptide of claim 1, wherein the peptide has a chromatographic purity of no less than 97%. 6. The purified peptide of claim 1, wherein the water content of the peptide is less than 10% of the total weight of the peptide. 7. The purified peptide of claim 1, wherein the peptide further contains less than 0.5% per weight of the peptide of one or more impurities selected from acetonitrile, alcohols, ammonium, and acetate. 8. The purified peptide of claim 7, wherein the peptide contains less than 300 ppm acetonitrile. 9. The purified peptide of claim 7, wherein the peptide contains less than 1000 ppm isopropanol. 10. The purified peptide of claim 7, wherein the peptide contains less than 600 ppm isopropanol. 11. The purified peptide of claim 7, wherein the peptide contains acetate at less than 0.25% of the total weight of the peptide. 12. The purified peptide of claim 1, wherein the peptide further contains topoisomers at less than 2% of the total weight of the peptide. 13. The purified peptide of claim 1, wherein the peptide further contains iso-Asp2-plecanatide (RTT 0.96-0.97) at less than 2% of the total weight of the peptide. 14. A process of purifying a peptide comprising the GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-54 and 56-251, the process comprising: providing a first peptide solution comprising a peptide comprising the GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-54 and 56-251, water, and acetonitrile; loading a C18 or polymeric adsorbent column with the first peptide solution to adsorb the peptide onto the C18 or polymeric adsorbent column, eluting the peptide off the C18 or polymeric adsorbent column with an alcohol aqueous solution to form a second peptide solution, reducing the amount of alcohol in the second peptide solution, and lyophilizing the second peptide solution such that a dry peptide is obtained. 15. The process of claim 14, wherein the alcohol aqueous solution comprises isopropanol. 16. The process of claim 15, wherein the isopropanol content in the alcohol aqueous solution is about 40% of the total weight of the peptide. 17. The process of claim 14, wherein the first peptide solution further comprises acetamide. 18. The process of claim 14, wherein the first peptide solution further comprises acetic acid at 0.2% of the total weight of the peptide or triethylamine phosphate at 1% of the total weight of the peptide. 19. The process of claim 14, wherein the amount of alcohol in the second peptide solution is reduced by rotoevaporation. 20. The process of claim 14, wherein the alcohol in the second peptide solution is reduced to less than 5% of the total weight of the peptide. 21. The process of claim 20, wherein the alcohol in the second peptide solution is isopropanol. 22. The process of claim 15, further comprising dissolving the dry peptide in water to form a third peptide solution after lyophilization. 23. The process of claim 22, wherein the third peptide solution further comprises ammonium hydroxide or ammonium acetate. 24. The process of claim 22, further comprising lyophilizing the third peptide solution such that a purified peptide is obtained.